ArticleFrontiers in public health2025
Inflammatory markers partially mediate the association between volatile organic compounds exposure and hyperlipidemia: a nationally representative cross-sectional study from NHANES.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While studies have explored associations between volatile organic compounds (VOCs) and metabolic diseases, evidence specifically linking VOCs to hyperlipidemia remains limited. This study aimed to examine the association between urinary VOC metabolites and hyperlipidemia prevalence in U.S. adults. Methods: Leveraging data from the 2011-2018 National Health and Nutrition Examination Survey (NHANES), this study employed weighted logistic regression, restricted cubic spline (RCS) models, weighted quantile sum (WQS) regression, quantile-based g-computation (qgcomp), and Bayesian kernel machine regression (BKMR) to evaluate associations of individual and mixed VOC exposures with hyperlipidemia. All models were adjusted for covariates including sex, age, race/ethnicity, poverty income ratio (PIR), education level, marital status, body mass index (BMI), smoking status, alcohol consumption, and urinary creatinine. Subgroup analyses assessed effect modifications by sex and age. Multiple-mediator analysis examined the roles of inflammatory biomarkers (white blood cell, lymphocyte, and neutrophil counts) in the association between VOC exposure and hyperlipidemia. Results: Among 1,979 included participants, weighted logistic regression identified 13 VOC metabolites significantly associated with increased hyperlipidemia risk. Subgroup analyses revealed stronger effects in females and individuals aged <60 years. The RCS model demonstrated positive linear dose-response relationships for hyperlipidemia risk with exposure to xylene, N, N-dimethylformamide, acrylonitrile, crotonaldehyde, 1,3-butadiene, and styrene. Mixture analyses showed significant positive associations via both WQS (1.312 [1.073, 1.606]) and qgcomp (1.296 [1.035, 1.623]), with N, N-dimethylformamide being primary contributor. However, BKMR detected no significant association. Multiple-mediator analysis indicated that inflammatory markers partially mediated the association between the VOC mixture and hyperlipidemia, and WBC was the leading mediator, accounting for 15.094% of the mediated effect. Conclusion: This study demonstrated significant positive associations of both individual and mixed VOC exposures with hyperlipidemia, with differential susceptibility observed in females and individuals aged <60 years. N, N-dimethylformamide contributed most to the association, and this effect was partly mediated by inflammatory biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.